Status:
COMPLETED
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Chronic Myeloproliferative Disorders
Fanconi Anemia
Eligibility:
All Genders
1-55 years
Brief Summary
RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn...
Detailed Description
OBJECTIVES: * Identify the specific molecular function of the Fanconi anemia (FA) complementing gene products in hematopoietic progenitor cells from patients and normal volunteers. * Identify functio...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- Diagnosis of one of the following:
- Fanconi's anemia requiring bone marrow biopsy as part of standard care (adults and children)
- Myeloproliferative disorder or myeloma (adults)
- Healthy volunteer, meeting 1 of the following criteria:
- Over 18 years of age
- Bone marrow transplant donor (children)
- PATIENT CHARACTERISTICS:
- Hemoglobin \> 13 g/dL
- White blood cells (WBC) \> 4,000/mm³
- Platelet count \> 150,000/mm³
- No clinical signs or symptoms of acute or subacute infections (viral, bacterial, or fungal)
- No known blood abnormality (healthy volunteers)
- No allergies to lidocaine or xylocaine
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
June 1 1975
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 23 2016
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT00900055
Start Date
June 1 1975
End Date
August 23 2016
Last Update
July 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States, 97239-3098